Mainz Biomed B.V. (MYNZ) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
MYNZ EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
MYNZ Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 64.3% | -2091.2% | -2421.8% |
| 2023 | 56.9% | -2975.5% | -2936.5% |
| 2022 | 34.4% | -4990.6% | -4992.2% |
| 2021 | 30.8% | -1684.4% | -2024.8% |
| 2020 | 24.9% | -155.2% | -118.9% |
Download Data
Export MYNZ earnings history in CSV or JSON format
Free sign-in required to download data
Mainz Biomed B.V. (MYNZ) Earnings Overview
As of May 8, 2026, Mainz Biomed B.V. (MYNZ) reported trailing twelve-month net income of -$40M, reflecting -1280.2% year-over-year growth. The company earned $-41.42 per diluted share over the past four quarters, with a net profit margin of -2421.8%.
Looking at the long-term picture, MYNZ's historical earnings data spans multiple years. The company achieved its highest annual net income of -$586,895 in fiscal 2020.
Mainz Biomed B.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EXAS (-$208M net income, -6.4% margin), GKOS (-$189M net income, -37.0% margin), NTRA (-$208M net income, -9.0% margin), MYNZ has room to improve margins relative to the peer group. Compare MYNZ vs EXAS →
MYNZ Earnings vs Peers
Earnings metrics vs comparable public companies
MYNZ Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$22M | +17.7% | -$19M | $-22.36 | -2421.8% | -2091.2% |
| 2023 | -$26M | +0.6% | -$27M | $-1.62 | -2936.5% | -2975.5% |
| 2022 | -$26M | -126.3% | -$26M | $-1.87 | -4992.2% | -4990.6% |
| 2021 | -$12M | -1891.9% | -$10M | $-1.67 | -2024.8% | -1684.4% |
| 2020 | $-586,895 | +38.7% | $-766,090 | $-0.05 | -118.9% | -155.2% |
| 2019 | $-957,055 | - | $-921,909 | $-0.10 | -340.1% | -327.6% |
See MYNZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MYNZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MYNZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMYNZ — Frequently Asked Questions
Quick answers to the most common questions about buying MYNZ stock.
Is MYNZ growing earnings?
MYNZ EPS fell to $-41.42, with earnings declining -1280.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-40M.
What are MYNZ's profit margins?
Mainz Biomed B.V. net margin is -2421.8%, with operating margin at -2091.2%. Below-average margins reflect competitive or cost pressures.
How consistent are MYNZ's earnings?
MYNZ earnings data spans 2019-2024. The declining earnings trend is -1280.2% YoY. Historical data enables comparison across business cycles.